Market Overview

Cytori Therapeutics (NASDAQ: CYTX) Shares Fall On News Of Launch Delay


Analysts at Piper Jaffray reiterated their underweight rating for Cytori Therapeutics (NASDAQ: CYTX) on news that Cytori’s Celution system launch will be delayed.

Analysts at Piper Jaffray noted that “shares of CYTX are down 36% over the last four trading sessions since Cytori reported that the FDA requested a PMA approval path for the Celution system last week. This pushes out our U.S. approval assumptions to 2013.” They also stated, “Last week, Cytori management reported that the FDA requested a Pre-Market Approval (PMA) path for the Celution system in soft tissue repair requiring at least one additional clinical study for approval.”

Piper Jaffray reiterated its underweight rating and set a $3 price target for CYTX.

Posted-In: Chad Messer Edward Tenthoff Krishna Gorti Piper JaffrayAnalyst Color Analyst Ratings


Related Articles (PMA + CYTX)

View Comments and Join the Discussion!

Latest Ratings

VIACJP MorganReinstates50.0
NUVASVB LeerinkMaintains92.0
SRPTCantor FitzgeraldMaintains211.0
LULUGoldman SachsMaintains219.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Chart Presentation: Trend Shift

Dollar Dipped to a Six-Week Low on a Trade-Weighed Basis